Translational Pharmacokinetic-Pharmacodynamic Modeling and Simulation: Optimizing 5-Fluorouracil Dosing in Children With Pediatric Ependymoma.

Autor: Daryani, VM¹, Patel, YT¹, Tagen, M², Turner, DC³, Carcaboso, AM⁴, Atkinson, JM⁵, Gajjar, A⁶, Gilbertson, RJ⁷, Wright, KD⁶, Stewart, CF¹

Publikováno v: CPT: Pharmacometrics & Systems Pharmacology. Apr2016, Vol. 5 Issue 4, p211-221. 11p.

LRRK2 Inhibition by BIIB122 in Healthy Participants and Patients with Parkinson's Disease.

Autor: Jennings D; SeniorClinical Scientist - Clinical Development, Denali Therapeutics Inc, South San Francisco, California, USA., Huntwork-Rodriguez S; SeniorClinical Scientist - Clinical Development, Denali Therapeutics Inc, South San Francisco, California, USA., Vissers MFJM; Centre for Human Drug Research, Leiden, the Netherlands.; Department of Clinical Neuropharmacology, Leiden University Medical Center, Leiden, the Netherlands., Daryani VM; SeniorClinical Scientist - Clinical Development, Denali Therapeutics Inc, South San Francisco, California, USA., Diaz D; SeniorClinical Scientist - Clinical Development, Denali Therapeutics Inc, South San Francisco, California, USA., Goo MS; SeniorClinical Scientist - Clinical Development, Denali Therapeutics Inc, South San Francisco, California, USA., Chen JJ; SeniorClinical Scientist - Clinical Development, Denali Therapeutics Inc, South San Francisco, California, USA., Maciuca R; SeniorClinical Scientist - Clinical Development, Denali Therapeutics Inc, South San Francisco, California, USA., Fraser K; Biogen Inc, Cambridge, Massachusetts, USA., Mabrouk OS; Biogen Inc, Cambridge, Massachusetts, USA., van de Wetering de Rooij J; SeniorClinical Scientist - Clinical Development, Denali Therapeutics Inc, South San Francisco, California, USA.; PRA Health Sciences, Groningen, the Netherlands., Heuberger JAAC; Centre for Human Drug Research, Leiden, the Netherlands., Groeneveld GJ; Centre for Human Drug Research, Leiden, the Netherlands.; Department of Clinical Neuropharmacology, Leiden University Medical Center, Leiden, the Netherlands., Borin MT; SeniorClinical Scientist - Clinical Development, Denali Therapeutics Inc, South San Francisco, California, USA., Cruz-Herranz A; SeniorClinical Scientist - Clinical Development, Denali Therapeutics Inc, South San Francisco, California, USA., Graham D; Biogen Inc, Cambridge, Massachusetts, USA., Scearce-Levie K; SeniorClinical Scientist - Clinical Development, Denali Therapeutics Inc, South San Francisco, California, USA., De Vicente J; SeniorClinical Scientist - Clinical Development, Denali Therapeutics Inc, South San Francisco, California, USA., Henry AG; SeniorClinical Scientist - Clinical Development, Denali Therapeutics Inc, South San Francisco, California, USA., Chin P; SeniorClinical Scientist - Clinical Development, Denali Therapeutics Inc, South San Francisco, California, USA., Ho C; SeniorClinical Scientist - Clinical Development, Denali Therapeutics Inc, South San Francisco, California, USA., Troyer MD; SeniorClinical Scientist - Clinical Development, Denali Therapeutics Inc, South San Francisco, California, USA.

Publikováno v: Movement disorders : official journal of the Movement Disorder Society [Mov Disord] 2023 Mar; Vol. 38 (3), pp. 386-398. Date of Electronic Publication: 2023 Feb 18.

Brain delivery and activity of a lysosomal enzyme using a blood-brain barrier transport vehicle in mice.

Autor: Ullman JC; Denali Therapeutics Inc., 161 Oyster Point Blvd., South San Francisco, CA 94080, USA., Arguello A; Denali Therapeutics Inc., 161 Oyster Point Blvd., South San Francisco, CA 94080, USA., Getz JA; Denali Therapeutics Inc., 161 Oyster Point Blvd., South San Francisco, CA 94080, USA., Bhalla A; Denali Therapeutics Inc., 161 Oyster Point Blvd., South San Francisco, CA 94080, USA., Mahon CS; Denali Therapeutics Inc., 161 Oyster Point Blvd., South San Francisco, CA 94080, USA., Wang J; Denali Therapeutics Inc., 161 Oyster Point Blvd., South San Francisco, CA 94080, USA., Giese T; Denali Therapeutics Inc., 161 Oyster Point Blvd., South San Francisco, CA 94080, USA., Bedard C; Denali Therapeutics Inc., 161 Oyster Point Blvd., South San Francisco, CA 94080, USA., Kim DJ; Denali Therapeutics Inc., 161 Oyster Point Blvd., South San Francisco, CA 94080, USA., Blumenfeld JR; Denali Therapeutics Inc., 161 Oyster Point Blvd., South San Francisco, CA 94080, USA., Liang N; Denali Therapeutics Inc., 161 Oyster Point Blvd., South San Francisco, CA 94080, USA., Ravi R; Denali Therapeutics Inc., 161 Oyster Point Blvd., South San Francisco, CA 94080, USA., Nugent AA; Denali Therapeutics Inc., 161 Oyster Point Blvd., South San Francisco, CA 94080, USA., Davis SS; Denali Therapeutics Inc., 161 Oyster Point Blvd., South San Francisco, CA 94080, USA., Ha C; Denali Therapeutics Inc., 161 Oyster Point Blvd., South San Francisco, CA 94080, USA., Duque J; Denali Therapeutics Inc., 161 Oyster Point Blvd., South San Francisco, CA 94080, USA., Tran HL; Denali Therapeutics Inc., 161 Oyster Point Blvd., South San Francisco, CA 94080, USA., Wells RC; Denali Therapeutics Inc., 161 Oyster Point Blvd., South San Francisco, CA 94080, USA., Lianoglou S; Denali Therapeutics Inc., 161 Oyster Point Blvd., South San Francisco, CA 94080, USA., Daryani VM; Denali Therapeutics Inc., 161 Oyster Point Blvd., South San Francisco, CA 94080, USA., Kwan W; Denali Therapeutics Inc., 161 Oyster Point Blvd., South San Francisco, CA 94080, USA., Solanoy H; Denali Therapeutics Inc., 161 Oyster Point Blvd., South San Francisco, CA 94080, USA., Nguyen H; Denali Therapeutics Inc., 161 Oyster Point Blvd., South San Francisco, CA 94080, USA., Earr T; Denali Therapeutics Inc., 161 Oyster Point Blvd., South San Francisco, CA 94080, USA., Dugas JC; Denali Therapeutics Inc., 161 Oyster Point Blvd., South San Francisco, CA 94080, USA., Tuck MD; Mass Spectrometry Research Center, Vanderbilt University, 9160 MRB III, 465 21 Avenue South, Nashville, TN 37240, USA., Harvey JL; Mass Spectrometry Research Center, Vanderbilt University, 9160 MRB III, 465 21 Avenue South, Nashville, TN 37240, USA., Reyzer ML; Mass Spectrometry Research Center, Vanderbilt University, 9160 MRB III, 465 21 Avenue South, Nashville, TN 37240, USA., Caprioli RM; Mass Spectrometry Research Center, Vanderbilt University, 9160 MRB III, 465 21 Avenue South, Nashville, TN 37240, USA., Hall S; Denali Therapeutics Inc., 161 Oyster Point Blvd., South San Francisco, CA 94080, USA., Poda S; Denali Therapeutics Inc., 161 Oyster Point Blvd., South San Francisco, CA 94080, USA., Sanchez PE; Denali Therapeutics Inc., 161 Oyster Point Blvd., South San Francisco, CA 94080, USA., Dennis MS; Denali Therapeutics Inc., 161 Oyster Point Blvd., South San Francisco, CA 94080, USA., Gunasekaran K; Denali Therapeutics Inc., 161 Oyster Point Blvd., South San Francisco, CA 94080, USA., Srivastava A; Denali Therapeutics Inc., 161 Oyster Point Blvd., South San Francisco, CA 94080, USA., Sandmann T; Denali Therapeutics Inc., 161 Oyster Point Blvd., South San Francisco, CA 94080, USA., Henne KR; Denali Therapeutics Inc., 161 Oyster Point Blvd., South San Francisco, CA 94080, USA., Thorne RG; Denali Therapeutics Inc., 161 Oyster Point Blvd., South San Francisco, CA 94080, USA., Di Paolo G; Denali Therapeutics Inc., 161 Oyster Point Blvd., South San Francisco, CA 94080, USA., Astarita G; Denali Therapeutics Inc., 161 Oyster Point Blvd., South San Francisco, CA 94080, USA., Diaz D; Denali Therapeutics Inc., 161 Oyster Point Blvd., South San Francisco, CA 94080, USA., Silverman AP; Denali Therapeutics Inc., 161 Oyster Point Blvd., South San Francisco, CA 94080, USA., Watts RJ; Denali Therapeutics Inc., 161 Oyster Point Blvd., South San Francisco, CA 94080, USA., Sweeney ZK; Denali Therapeutics Inc., 161 Oyster Point Blvd., South San Francisco, CA 94080, USA., Kariolis MS; Denali Therapeutics Inc., 161 Oyster Point Blvd., South San Francisco, CA 94080, USA. kariolis@dnli.com henry@dnli.com., Henry AG; Denali Therapeutics Inc., 161 Oyster Point Blvd., South San Francisco, CA 94080, USA. kariolis@dnli.com henry@dnli.com.

Publikováno v: Science translational medicine [Sci Transl Med] 2020 May 27; Vol. 12 (545).

A phase II trial evaluating the feasibility of adding bevacizumab to standard osteosarcoma therapy.

Autor: Navid F; Department of Oncology, St. Jude Children's Research Hospital, Memphis, TN.; Department of Pediatrics, University of Tennessee Health Science Center, Memphis, TN., Santana VM; Department of Oncology, St. Jude Children's Research Hospital, Memphis, TN.; Department of Pediatrics, University of Tennessee Health Science Center, Memphis, TN., Neel M; Department of Surgery, St. Jude Children's Research Hospital, Memphis, TN., McCarville MB; Department of Diagnostic Imaging, St. Jude Children's Research Hospital, Memphis, TN.; Department of Radiology, University of Tennessee Health Science Center, Memphis, TN., Shulkin BL; Department of Diagnostic Imaging, St. Jude Children's Research Hospital, Memphis, TN.; Department of Radiology, University of Tennessee Health Science Center, Memphis, TN., Wu J; Department of Biostatistics, St. Jude Children's Research Hospital, Memphis, TN., Billups CA; Department of Biostatistics, St. Jude Children's Research Hospital, Memphis, TN., Mao S; Department of Biostatistics, St. Jude Children's Research Hospital, Memphis, TN., Daryani VM; Department of Pharmaceutical Sciences, St. Jude Children's Research Hospital, Memphis, TN., Stewart CF; Department of Pharmaceutical Sciences, St. Jude Children's Research Hospital, Memphis, TN., Kunkel M; Department of Oncology, St. Jude Children's Research Hospital, Memphis, TN., Smith W; Department of Oncology, St. Jude Children's Research Hospital, Memphis, TN., Ward D; Department of Pharmaceutical Services, St. Jude Children's Research Hospital, Memphis, TN., Pappo AS; Department of Oncology, St. Jude Children's Research Hospital, Memphis, TN.; Department of Pediatrics, University of Tennessee Health Science Center, Memphis, TN., Bahrami A; Department of Pathology, St. Jude Children's Research Hospital, Memphis, TN., Loeb DM; Department of Oncology, Division of Pediatric Oncology, Sidney Kimmel Comprehensive Cancer Center, Johns Hopkins University, Baltimore, MD., Reikes Willert J; Pediatric Hematology/Oncology/Blood and Marrow Transplant, Rady Children's Hospital, San Diego, CA., Rao BN; Department of Surgery, St. Jude Children's Research Hospital, Memphis, TN.; Department of Surgery, College of Medicine, University of Tennessee Health Science Center, Memphis, TN., Daw NC; Division of Pediatrics, MD Anderson Cancer Center, Houston, TX.

Publikováno v: International journal of cancer [Int J Cancer] 2017 Oct 01; Vol. 141 (7), pp. 1469-1477. Date of Electronic Publication: 2017 Jul 03.

A molecular biology and phase II study of imetelstat (GRN163L) in children with recurrent or refractory central nervous system malignancies: a pediatric brain tumor consortium study.

Autor: Salloum R; Brain Tumor Center, Cancer and Blood Diseases Institute, Cincinnati Children's Hospital Medical Center, MLC 7013, 3333 Burnet Ave, Cincinnati, OH, 45229, USA., Hummel TR; Brain Tumor Center, Cancer and Blood Diseases Institute, Cincinnati Children's Hospital Medical Center, MLC 7013, 3333 Burnet Ave, Cincinnati, OH, 45229, USA., Kumar SS; Brain Tumor Center, Cancer and Blood Diseases Institute, Cincinnati Children's Hospital Medical Center, MLC 7013, 3333 Burnet Ave, Cincinnati, OH, 45229, USA., Dorris K; Children's Hospital Colorado, Aurora, CO, USA., Li S; University of North Carolina, Charlotte, NC, USA., Lin T; St Jude Children's Research Hospital, Memphis, TN, USA., Daryani VM; St Jude Children's Research Hospital, Memphis, TN, USA., Stewart CF; St Jude Children's Research Hospital, Memphis, TN, USA., Miles L; Nemours Children's Hospital, Orlando, FL, USA., Poussaint TY; Boston Children's Hospital, Boston, MA, USA., Stevenson C; Brain Tumor Center, Cancer and Blood Diseases Institute, Cincinnati Children's Hospital Medical Center, MLC 7013, 3333 Burnet Ave, Cincinnati, OH, 45229, USA., Goldman S; Anne and Robert H. Lurie Children's Hospital of Chicago, Chicago, IL, USA., Dhall G; Children's Hospital of Los Angeles, Los Angeles, CA, USA., Packer R; Children's National Medical Center, Washington, DC, USA., Fisher P; Lucile Packard Children's Hospital Stanford, Palo Alto, CA, USA., Pollack IF; Children's Hospital of Pittsburgh, Pittsburgh, PA, USA., Fouladi M; Brain Tumor Center, Cancer and Blood Diseases Institute, Cincinnati Children's Hospital Medical Center, MLC 7013, 3333 Burnet Ave, Cincinnati, OH, 45229, USA., Boyett J; St Jude Children's Research Hospital, Memphis, TN, USA., Drissi R; Brain Tumor Center, Cancer and Blood Diseases Institute, Cincinnati Children's Hospital Medical Center, MLC 7013, 3333 Burnet Ave, Cincinnati, OH, 45229, USA. rachid.drissi@cchmc.org.

Publikováno v: Journal of neuro-oncology [J Neurooncol] 2016 Sep; Vol. 129 (3), pp. 443-451. Date of Electronic Publication: 2016 Jun 27.